Development of nucleotide therapeutics: strategies and considerations

REGISTER NOW

Date: Thursday 5 September 2024 | 8:00 PDT | 11:00 EDT | 16:00 BST | 17:00 CEST

Produced by Cytiva and presented by Nature Research Custom Media

RNA and DNA therapies are revolutionizing the field of medicine. These therapies target specific genes which are then silenced, expressed, or edited to treat various diseases. The advancement of cancer vaccine research has played a significant role in the rapid development and release of mRNA vaccines, gaining considerable attention and increased funding for research in this area.

Approved therapies and ongoing clinical projects often utilize oligonucleotides, which are short DNA or RNA molecules. The first oligonucleotide therapeutics received clinical approval in 1998. There are now more oligo-based drug candidates in advanced clinical stages compared to mRNA projects.

Oligonucleotide therapeutic approaches encompass a range of mechanisms of action, but each presents its own set of challenges. Understanding different mechanisms and associated challenges provides valuable insights into the development of nucleotide therapeutics.

This webcast will delve into the strategies and considerations essential for successful development of oligonucleotides. Topics covered will include synthesis, purification, analysis, and scale-up, providing a comprehensive overview of this exciting field.

Learn:

• Challenges for oligo therapeutics – from synthesis to delivery and safety
• Insights into the different purification strategies and which route to choose when
• How surface plasmon resonance (SPR) technology can aid the selection and deeper understanding of target binding

Unable to join the live event? Watch on demand. Register now to ensure that you receive information on how to gain access after the live event.

This webcast has been produced by Cytiva, who retails sole responsibility for content. About this content.

Speaker

Peter Guterstam, Senior Product Manager, Cytiva

Peter is Product Manager for nucleic acid processing products at Cytiva. He gained his MSc in Biotechnology from Uppsala University and BSc from Swedish University of Agricultural Sciences. He earned his PhD in Neurochemistry from Stockholm University in 2009 with a thesis on cell-penetrating peptides for delivery of oligo-therapeutics. He has been with Cytiva since 2003 and launched Primer Support 5G for solid phase oligosynthesis in 2012. Since Cytiva’s acquisition of Puridify, Peter has led development of products based on Fibro technology to complement Cytiva’s portfolio of chromatography resins and continues to further generate tailored solutions for the manufacture of Advanced Therapy Medicinal Products.

Moderator

Nikki Forrester, Freelance Science Writer and Editor

Nikki Forrester is a science journalist who covers biology, natural history, climate, and the culture of academic research. She earned a Ph.D. in ecology and evolutionary biology in 2019.